J0850 Cytomegalovirus IVIG Reimbursement | OpenPayer

Summary & Overview

HCPCS J0850: Cytomegalovirus Immune Globulin IV, per Vial

HCPCS Level II code J0850 denotes a vial of cytomegalovirus immune globulin intravenous (human), an infused biologic used to provide passive immunity against cytomegalovirus. Nationally, this injectable product is relevant in transplant medicine and for certain immunocompromised patients where CMV prophylaxis or treatment is indicated, making its billing and coverage practices important for hospitals and infusion centers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J0850, typical sites of service where the product is administered, and what to expect in payer coverage terms. The publication summarizes available benchmarks, common billing practices, and notable policy or coverage updates that affect reimbursement and utilization for this biologic. Practical guidance on where to locate related payer policies and billing considerations for infusion services is provided.

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ0850HCPCS Level IIimmune globulinintravenous infusionbiologic drugCMV prophylaxisinfusion centerhospital outpatientmedical billing

Billing Code Overview

HCPCS Level II code J0850 represents injection, cytomegalovirus immune globulin intravenous (human), per vial. This code denotes a parenteral biologic product intended for intravenous administration to provide passive immunity against cytomegalovirus.

Service type: Intravenous infusion / injectable biologic
Typical site of service: Inpatient hospital, outpatient hospital infusion center, ambulatory infusion center, or other medical office/clinic settings where intravenous biologic administration is performed

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical & Coding Specifications

Clinical Context

A 45-year-old solid-organ transplant recipient (renal transplant) is admitted for prophylaxis and treatment of cytomegalovirus (CMV) infection. The patient is CMV seropositive donor to seronegative recipient (D+/R−) and develops CMV viremia with rising viral load despite oral antiviral therapy intolerance or contraindication. Intravenous cytomegalovirus immune globulin (CMV-IVIG) is ordered as adjunctive therapy.

The clinical workflow: the transplant infectious disease clinician documents the indication and dose in the medical record. Pharmacy obtains and prepares the J0850 vial(s) under sterile conditions, labels them with lot number and expiration, and records them in the patient’s medication administration record. The nurse verifies consent and IV access, administers premedication if needed (antipyretic/antihistamine), and infuses CMV-IVIG per institutional infusion protocol while monitoring for infusion reactions. Post-infusion documentation includes lot numbers, vial count, administration time, infusion rate, patient tolerance, and any adverse reactions. Billing captures the number of vials administered using HCPCS J0850 with appropriate modifier(s) to reflect circumstances of service or drug handling.

Coding Specifications

Modifier	Description	When to Use
`11`	Normal service

HCPCS J7320: Hyaluronan (GenVisc 850) for Intra-articular Injection, 1 mg

HCPCS-J7527-EVEROLIMUS-ORAL-025-MG

HCPCS J7527: Everolimus, Oral, 0.25 mg

HCPCS-J0169-EPINEPHRINE-INJECTION-0-1-MG

HCPCS J0169: Epinephrine Injection, 0.1 mg

HCPCS-J3250-TRIMETHOBENZAMIDE-INJECTION-200MG

HCPCS J3250: Trimethobenzamide Injection, up to 200 mg

HCPCS-J3055-TALQUETAMAB-INJECTION-0-25-MG

HCPCS Level II J3055: Injection, talquetamab-tgvs, 0.25 mg

HCPCS-J1553-IMMUNE-GLOBULIN-YIMMUGO-100-MG-INJECTION

HCPCS Level II J1553: Immune Globulin (yimmugo) Injection, 100 mg

HCPCS-J3486-ZIPRASIDONE-INJECTION-10MG

HCPCS J3486: Injection, Ziprasidone Mesylate, 10 mg

HCPCS-J2212-METHYLNALTREXONE-INJECTION-0-1-MG

HCPCS J2212: Methylnaltrexone Injection, 0.1 mg

HCPCS-J1164-DILTIAZEM-INJECTION-0-5-MG

HCPCS J1164: Diltiazem Hydrochloride Injection, 0.5 mg

HCPCS-J7296-LEVONORGESTREL-IUD-KYLEENA-19-5-MG

HCPCS Level II J7296: Levonorgestrel IUD (Kyleena) 19.5 mg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`2080S00000X`	Transplant Surgery	Surgeons who manage perioperative care and may be involved in complex infusion decisions.
`207K00000X`	Infectious Disease	Specialists who direct use of CMV-IVIG for prophylaxis or treatment of CMV.
`363L00000X`	Clinical Pharmacology	Pharmacists and clinical pharmacologists who prepare IVIG and manage dosing.
`163W00000X`	Internal Medicine	Hospitalists and general internists who coordinate inpatient administration and monitoring.
`364S00000X`	Oncology	Oncology providers may administer IVIG for immunocompromised patients; relevant in hematopoietic transplant contexts.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B25.9`	Cytomegalovirus disease, unspecified	Primary diagnosis for symptomatic CMV infection warranting IV immune globulin in severe or refractory cases.
`B25.2`	Cytomegalovirus pneumonitis	CMV lung infection in immunocompromised patients where CMV-IVIG may be used adjunctively.
`B25.0`	Cytomegaloviral hepatitis	Severe hepatic CMV infection where adjunctive immune globulin may be considered.
`B25.8`	Other cytomegalovirus disease	Includes CMV manifestations (e.g., gastrointestinal) potentially treated with CMV-IVIG adjunctively.
`T86.10`	Unspecified complication of kidney transplant	Post-transplant complications including CMV infection management context.
`T86.12`	Infection and inflammatory reaction of transplanted kidney	Relevant when CMV contributes to infection in transplanted organ.
`Z94.0`	Kidney transplant status	Denotes transplant recipient status, increasing CMV risk and need for prophylactic/therapeutic IVIG.
`D80.9`	Immunodeficiency, unspecified	Underlying immunodeficiency increasing susceptibility to CMV and need for passive immunization.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Commonly used to report the infusion administration time for the first hour when CMV-IVIG is given in an outpatient infusion center.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary service)	Used to report additional infusion time beyond the first hour when CMV-IVIG administration exceeds 1 hour.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if a smaller dose is administered via subcutaneous or intramuscular route in an atypical scenario (rare for CMV-IVIG).
`36415`	Collection of venous blood by venipuncture	Often performed for pre-infusion viral load, serologies, or monitoring labs related to CMV treatment.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Represents the outpatient visit when the prescribing clinician evaluates the patient and documents the need for CMV-IVIG.

OpenPayer